# US 2020/0392133 A1 · Azaindole derivatives as rho- kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392133 A1
- Document ID: US20200392133A1
- Status: Published application
- Kind: A1
- Application number: 16/954,977
- Filed: 2018-12-14
- Published: 2020-12-17
- Earliest claimed: 2017-12-18
- Assignees: Chiesi Farmaceutici S.p.A.
- Applicants: CHIESI FARMACEUTICI S.p.A.
- Inventors: Alessandro ACCETTA; Fabio RANCATI; Christine EDWARDS; Andrea NUZZI
- Web page: https://patentgrep.com/patent/US20200392133A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 11/00: Drugs for disorders of the respiratory system
- C07D 487/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to compounds of formula I inhibiting Rho Kinase that are tyrosine analogues derivatives, processes of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

## Claims

### Claim 1

A compound of formula (I)
wherein
X1 is a carbon or a nitrogen atom;
p is zero or an integer from 1 to 3;
each R, when present, is H or halogen;
R1 is —H, —CN or (C1-C6) alkyl;
B is (C3-C8)heterocycloalkyl,
or
B is a group of formula R2R3N—(C1-C6) alkyl, optionally substituted by one or more substituents selected from hydroxyl, (C1-C6) alkyl, (C1-C6) hydroxyalkyl, (C1-C6) alkoxycarbonyl, (C3-C10) cycloalkoxycarbonyl, aryl (C1-C6) alkoxycarbonyl;
wherein
R2 and R3, the same or different, are selected from the group consisting of
—H,
(C1-C6) alkyl,
(C1-C6) hydroxyalkyl,
(C3-C8)heterocycloalkyl, further optionally substituted by one or more (C1-C6) alkyl;
or
B is a group of formula R2R3N—(C1-C6) alkyl, optionally substituted by one or more substituents selected from hydroxyl, (C1-C6) alkyl, (C1-C6) hydroxyalkyl, (C1-C6) alkoxycarbonyl, (C3-C10) cycloalkoxycarbonyl, aryl (C1-C6) alkoxycarbonyl;
wherein
R2 and R3, taken together with the nitrogen atom they are linked to, form a heterocyclic ring, preferably a 4 to 6 membered mono-cyclic saturated heterocyclic ring, wherein at least one further ring carbon atom is optionally replaced by at least one further group independently selected from N, NH, S or O and/or may bear an -oxo (═O) substituent group, said heterocyclic ring is further optionally including spiro disubstitution; and said heterocyclic ring in its turn is further optionally substituted by one or more substituents selected from hydroxyl, (C1-C6) alkyl, (C1-C6) hydroxyalkyl, (C1-C6) alkoxycarbonyl, (C3-C10) cycloalkoxycarbonyl, Aryl (C1-C6) alkoxycarbonyl;
or
B is a group of formula R2R3N—(C1-C6) alkyl, optionally substituted by one or more substituents selected from hydroxyl, (C1-C6) alkyl, (C1-C6) hydroxyalkyl, (C1-C6) alkoxycarbonyl, (C3-C10) cycloalkoxycarbonyl, aryl (C1-C6) alkoxycarbonyl;
wherein
R3 is selected from the group consisting of
—H,
(C1-C6) alkyl,
(C1-C6) hydroxyalkyl,
(C3-C8) heterocycloalkyl, further optionally substituted by one or more (C1-C6) alkyl;
R2 is a divalent group —(CH2)q—, wherein q is an integer from 1 to 3; said divalent group being connected to the carbon atom in ortho position on the adjacent phenyl ring to form a heterocyclic ring, preferably a 4 to 10 membered heterocyclic ring fused with the phenyl ring; said heterocyclic ring being optionally in its turn further substituted with one or more group selected from (C1-C6) alkyl, (C1-C6) hydroxyalkyl;
or
B is a divalent group —(CH2)s—, wherein s is an integer from 2 to 8, said divalent group being connected to the adjacent carbon in ortho position on the phenyl ring to form a fused ring; preferably a 4 to 10 membered monocyclic ring fused with the phenyl ring; said ring being further substituted with one or more —NH2;
and pharmaceutically acceptable salts and solvates thereof.

### Claim 2 (depends on 1)

A compound according to claim 1 wherein each of X1 is a carbon atom; represented by formula Ia:
and R, R1, B and p, are as in claim 1.

### Claim 3 (depends on 1)

A compound according to claim 1 wherein
X1 is a carbon or a nitrogen atom;
p is zero or an integer from 1 or 2;
each R, when present, is H or a halogen;
R1 is —H or (C1-C6) alkyl;
B is a group R2R3N—(C1-C6) alkyl, said alkyl being optionally substituted by one or more substituents selected from (C1-C6) alkyl and/or (C1-C6) hydroxyalkyl;
wherein
R2 and R3, the same or different, are selected from the group consisting of
—H,
(C1-C6) alkyl,
(C1-C6) hydroxyalkyl,
(C3-C8) heterocycloalkyl, further optionally substituted by one or more (C1-C6) alkyl;
or
R2 and R3, taken together with the nitrogen atom they are linked to, form a morpholinyl, 2,7-diazaspiro[4,4]nonan-2-yl or piperazinyl ring
further optionally substituted with one or more methyl;
and pharmaceutically acceptable salts and solvates thereof.

### Claim 4 (depends on 1)

A compound according to claim 1 wherein
X1 is a ring carbon atom;
p is zero or an integer from 1 to 3;
each R, when present, is H or a halogen;
R1 is H, —CN or methyl;
B is a (C3-C8)heterocycloalkyl selected from a1, a2 or a3:
or
B is a group of formula R2R3N—(C1-C6) alkyl, optionally substituted by one or more substituents selected from hydroxyl, (C1-C6) alkyl, (C1-C6) hydroxyalkyl, (C1-C6) alkoxycarbonyl, (C3-C10) cycloalkoxycarbonyl, aryl (C1-C6) alkoxycarbonyl;
wherein
R3 is selected from the group consisting of
—H,
(C1-C6) alkyl,
(C1-C6) hydroxyalkyl,
(C3-C8)heterocycloalkyl, further optionally substituted by one or more (C1-C6) alkyl;
R2 is a divalent group —(CH2)q—, q is an integer from 1 to 3, said divalent group being connected to the carbon atom in ortho position on the adjacent phenyl ring to form a heterobicyclic ring of formula a4, a5, a6, a7 or a8
wherein [1] represent the point of attachment of the heterobicyclic ring to the rest of the molecule via the ether bridge, and
said heterobicyclic ring being optionally in its turn further substituted with one or more (C1-C6) alkyl and/or (C1-C6) hydroxyalkyl group;
and pharmaceutically acceptable salts and solvates thereof.

### Claim 5 (depends on 1)

A compound according to claim 1 wherein
X1 is a carbon ring atom;
p is zero or an integer from 1 to 3;
each R, when present, is H or halogen;
R1 is methyl;
B is a divalent group —(CH2)s—, wherein s is an integer from 2 to 8, said divalent group being connected to the carbon atom in ortho position of the same phenyl ring to form a bicyclic hydrocarbon ring selected from b1 or b2:
wherein [1] represents the point of attachment of the heterobicyclic ring to the rest of the molecule via the ether bridge, and
said bicyclic hydrocarbon ring is further substituted with one or more —NH2;
and pharmaceutically acceptable salts and solvates thereof.

### Claim 6 (depends on 1)

A compound according to claim 1, wherein
X1 is a carbon or a nitrogen ring atom;
p is zero or an integer from 1 to 3;
each R, when present, is fluoro;
R1 is —H, —CN or methyl,
B is a azetidinyl (a1), pyrrolidinyl (a2) or piperazinyl (a3) ring;
or
B is a group R2R3N—(C1-C6) alkyl, the —(C1-C6) alkyl being optionally substituted by one or more substituents selected from hydroxyl, methyl, hydroxymethyl and cyclopropyl;
wherein
R2 and R3, the same or different, are selected from the group consisting of
—H,
methyl
hydroxyethyl
pyranyl, piperidinyl, further optionally substituted by one or more methyl;
or
R2 and R3, taken together with the nitrogen atom they are linked to, form a pyrrolidinyl, morpholinyl, 2,7-diazaspiro[4,4]nonan-2-yl or 4-methylpiperazin-1-yl ring;
or
R3 is selected from the group consisting of:
—H,
-methyl; and
R2 is connected to the carbon atom in ortho position on the adjacent phenyl ring to form a heterobicyclic ring selected from 5-methylisoindoline (a4), 6-methyl-1,2,3,4-tetrahydroisoquinoline (a5), 7-methyl-2,3,4,5-tetrahydro-1H-benzo[c]azepine (a6) and 7-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine (a7) and 7-methyl-1,2,3,4-tetrahydroisoquinoline (a8);
said heterocyclic ring being optionally in its turn further substituted with one or more methyl and/or hydroxymethyl groups;
or
B is a bicyclic hydrocarbon ring selected from 2,3-dihydro-1H-indene-5yl (b1) and 1,2,3,4-tetrahydronaphthalene-6yl (b2);
said bicyclic hydrocarbon ring being further optionally in its turn substituted with one or more —NH2;
and pharmaceutically acceptable salts and solvates thereof.

### Claim 7 (depends on 1)

A compound according to claim 1 selected from:
7-((3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)-1,2,3,4-tetrahydroisoquinoline;
4-(isoindolin-5-yloxy)-3-methyl-1H-pyrrolo[2,3-b]pyridine;
N-methyl-1-(4-((3-methyl-H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)methanamine;
2-(4-((1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)ethanamine;
7-((3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
7-((5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-1,2,3,4-tetrahydroisoquinoline;
5-methyl-4-(4-(pyrrolidin-3-yl)phenoxy)-7H-pyrrolo[2,3-d]pyrimidine;
2-(4-((5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)ethanamine;
(4-((5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)methanamine;
2-methyl-7-((3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)-1,2,3,4-tetrahydroisoquinoline;
6-((3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)-1,2,3,4-tetrahydroisoquinoline;
(3-fluoro-4-((3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)methanamine;
3-methyl-4-(4-(piperazin-2-yl)phenoxy)-1H-pyrrolo[2,3-b]pyridine;
5-((3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)-2,3-dihydro-1H-inden-2-amine;
7-((3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)-2,3,4,5-tetrahydro-H-benzo[c]azepine;
8-((3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)-2,3,4,5-tetrahydro-1H-benzo[c]azepine;
4-(4-(azetidin-3-yl)phenoxy)-3-methyl-1H-pyrrolo[2,3-b]pyridine;
3-methyl-4-(4-(pyrrolidin-2-yl)phenoxy)-1H-pyrrolo[2,3-b]pyridine;
2-(4-((3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)ethanamine;
3-methyl-4-(4-(pyrrolidin-3-yl)phenoxy)-1H-pyrrolo[2,3-b]pyridine;
(4-((3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)methanamine;
3-methyl-4-(4-(2-(pyrrolidin-1-yl)ethyl)phenoxy)-1H-pyrrolo[2,3-b]pyridine;
1-(3-fluoro-4-((3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)ethanamine;
1-(4-((3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)ethanamine;
2-(4-((3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)propan-2-amine;
6-((3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)-1,2,3,4-tetrahydronaphthalen-1-amine;
4-(4-((3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)benzyl)morpholine;
N-(4-((3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)benzyl)tetrahydro-2H-pyran-4-amine;
N,N-dimethyl-1-(4-((3-methyl-H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)methanamine;
1-methyl-N-(4-((3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)benzyl)piperidin-4-amine;
2-((4-((3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)benzyl)amino)ethanol;
4-(4-(2,7-diazaspiro[4.4]nonan-2-ylmethyl)phenoxy)-3-methyl-1H-pyrrolo[2,3-b]pyridine;
3-methyl-4-(4-((4-methylpiperazin-1-yl)methyl)phenoxy)-1H-pyrrolo[2,3-b]pyridine;
4-((1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile;
(4-((1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)-3,5-difluorophenyl)methanamine;
(S)-2-amino-3-(3-fluoro-4-((3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)propan-1-ol;
(S)-2-amino-3-(4-((3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)propan-1-ol;
2-amino-2-(4-((3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)ethanol;
(R)-(7-((3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)-1,2,3,4-tetrahydroisoquinolin-3-yl)methanol;
First Eluted enantiomer of 3-methyl-4-(4-(pyrrolidin-2-yl)phenoxy)-1H-pyrrolo[2,3-b]pyridine;
Second Eluted enantiomer of 3-methyl-4-(4-(pyrrolidin-2-yl)phenoxy)-1H-pyrrolo[2,3-b]pyridine
or pharmaceutically acceptable salts and solvates thereof.

### Claim 8 (depends on 1)

A pharmaceutical composition comprising a compound as defined in claim 1, or a pharmaceutically acceptable salt thereof in admixture with one or more pharmaceutically acceptable carrier or excipient.

### Claim 9 (depends on 8)

A pharmaceutical composition according to claim 8 suitable to be administered by inhalation, such as inhalable powders, propellant-containing metering aerosols or propellant-free inhalable formulations.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

A method for preventing and/or treating a pulmonary disease in a subject in need thereof comprising administering the compound according to claim 1 to the subject.

### Claim 12 (depends on 11)

The method according to claim 11 wherein the pulmonary disease is selected from the group consisting of asthma, chronic obstructive pulmonary disease COPD, idiopathic pulmonary fibrosis (IPF), pulmonary hypertension (PH) and specifically Pulmonary Arterial Hypertension (PAH).

### Claim 13 (depends on 1)

A compound as defined in claim 1, in combination with one or more active ingredients selected from the classes consisting of organic nitrates and NO donors; inhaled NO; stimulator of soluble guanylate cyclase (sGC); prostaciclin analogue PGI2 and agonist of prostacyclin receptors; compounds that inhibit the degradation of cyclic guanosine monophosphate (cGMP) and/or cyclic adenosine monophosphate (cAMP); human neutrophilic elastase inhibitors; compounds inhibiting the signal transduction cascade; active substances for lowering blood pressure; neutral endopeptidase inhibitors; osmotic agents; ENaC blockers; anti-inflammatories including corticosteroids and antagonists of chemokine receptors; bronchodilators; antihistamine drugs; anti-tussive drugs; antibiotics and DNase drug substance and selective cleavage agents; agents that inhibit ALK5 and/or ALK4 phosphorylation of Smad2 and Smad3; tryptophan hydroylase 1 (TPH1) inhibitors and multi-kinase inhibitors.

### Claim 14 (depends on 8)

A device comprising the pharmaceutical composition according to claim 8, which may be a single- or multi-dose dry powder inhaler, a metered dose inhaler or a soft mist nebulizer.

### Claim 15 (depends on 7)

A pharmaceutical composition comprising a compound as defined in claim 7, or a pharmaceutically acceptable salt thereof, either alone or in combination with another one or more active ingredients, in admixture with one or more pharmaceutically acceptable carriers or excipients.

### Claim 16 (depends on 15)

The pharmaceutical composition according to claim 15 suitable to be administered by inhalation, such as inhalable powders, propellant-containing metering aerosols or propellant-free inhalable formulations.

### Claim 17 (depends on 7)

A method for preventing and/or treating a pulmonary disease in a subject in need thereof comprising administering the compound according to claim 7 to the subject.

### Claim 18 (depends on 7)

A method for preventing and/or treating a pulmonary disease in a subject comprising administering to the subject the compound according to claim 7, wherein the pulmonary disease is selected from the group consisting of asthma, chronic obstructive pulmonary disease COPD, idiopathic pulmonary fibrosis (IPF), pulmonary hypertension (PH) and specifically Pulmonary Arterial Hypertension (PAH).

### Claim 19 (depends on 7)

A compound as defined in claim 7, in combination with one or more active ingredients selected from the classes consisting of organic nitrates and NO donors; inhaled NO; stimulator of soluble guanylate cyclase (sGC); prostaciclin analogue PGI2 and agonist of prostacyclin receptors; compounds that inhibit the degradation of cyclic guanosine monophosphate (cGMP) and/or cyclic adenosine monophosphate (cAMP); human neutrophilic elastase inhibitors; compounds inhibiting the signal transduction cascade; active substances for lowering blood pressure; neutral endopeptidase inhibitors; osmotic agents; ENaC blockers; anti-inflammatories including corticosteroids and antagonists of chemokine receptors; bronchodilators; antihistamine drugs; anti-tussive drugs; antibiotics and DNase drug substance and selective cleavage agents; agents that inhibit ALK5 and/or ALK4 phosphorylation of Smad2 and Smad3; tryptophan hydroylase 1 (TPH1) inhibitors and multi-kinase inhibitors.

### Claim 20 (depends on 15)

A device comprising the pharmaceutical composition according to claim 15, which may be a single- or multi-dose dry powder inhaler, a metered dose inhaler, or a soft mist nebulizer.

### Claim 21 (depends on 8)

A method for preventing and/or treating a pulmonary disease in a subject in need thereof comprising administering the pharmaceutical composition according to claim 8 to the subject.
